BR112021022225A2 - Composto, pró-droga e composição farmacêutica - Google Patents

Composto, pró-droga e composição farmacêutica

Info

Publication number
BR112021022225A2
BR112021022225A2 BR112021022225A BR112021022225A BR112021022225A2 BR 112021022225 A2 BR112021022225 A2 BR 112021022225A2 BR 112021022225 A BR112021022225 A BR 112021022225A BR 112021022225 A BR112021022225 A BR 112021022225A BR 112021022225 A2 BR112021022225 A2 BR 112021022225A2
Authority
BR
Brazil
Prior art keywords
compound
prodrug
pharmaceutical composition
cancer
compounds
Prior art date
Application number
BR112021022225A
Other languages
English (en)
Inventor
Brigitte Renoux
Rémi Chatre
Sébastien Papot
Original Assignee
Centre Nat Rech Scient
Seekyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Seekyo filed Critical Centre Nat Rech Scient
Publication of BR112021022225A2 publication Critical patent/BR112021022225A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composto, pró-droga e composição farmacêutica. a presente invenção se refere a um composto com a seguinte fórmula (i): bem como as pró-drogas correspondentes, composições farmacêuticas compreendendo os referidos compostos, em particular para o tratamento do câncer.
BR112021022225A 2019-05-06 2020-05-06 Composto, pró-droga e composição farmacêutica BR112021022225A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305574 2019-05-06
PCT/EP2020/062617 WO2020225323A1 (en) 2019-05-06 2020-05-06 New therapeutic vectors and prodrugs for treating cancers

Publications (1)

Publication Number Publication Date
BR112021022225A2 true BR112021022225A2 (pt) 2021-12-28

Family

ID=66625887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022225A BR112021022225A2 (pt) 2019-05-06 2020-05-06 Composto, pró-droga e composição farmacêutica

Country Status (8)

Country Link
US (1) US20220227741A1 (pt)
EP (1) EP3965893A1 (pt)
JP (1) JP2022531612A (pt)
CN (1) CN114173877A (pt)
AU (1) AU2020268749A1 (pt)
BR (1) BR112021022225A2 (pt)
CA (1) CA3139378A1 (pt)
WO (1) WO2020225323A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
FR3017298B1 (fr) * 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
US11666657B2 (en) * 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体

Also Published As

Publication number Publication date
JP2022531612A (ja) 2022-07-07
US20220227741A1 (en) 2022-07-21
EP3965893A1 (en) 2022-03-16
WO2020225323A1 (en) 2020-11-12
CN114173877A (zh) 2022-03-11
AU2020268749A1 (en) 2021-12-02
CA3139378A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
BR112018007381A2 (pt) compostos úteis como imunomoduladores
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
CO6480975A2 (es) Mimetico de smac
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU20110052A7 (es) Compuestos orgánicos
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
UY36702A (es) Piridinas sustituidas y métodos de uso
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
BR112022012126A2 (pt) Compostos antelmínticos compreendendo uma estrutura quinolínica